Tepilta® Versus Oxetacaine, Antacids and Placebo
Clinical Trial to Assess the Efficacy of Fixed Combination Product Tepilta® in the Treatment of Radiation-induced Oesophagitis Compared to Its Active Ingredients Oxetacaine and Antacids, and to Placebo
Sponsor: Clinipace Worldwide
This PHASE3 trial investigates Radiation-induced Oesophagitis and is currently terminated or withdrawn. Clinipace Worldwide leads this study, which shows 14 recorded versions since 2011 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Mar 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Mar 2022 [monthly]
Terminated PHASE3
▶ Show 9 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE3
-
Jun 2017 — Aug 2017 [monthly]
Terminated PHASE3
-
May 2017 — Jun 2017 [monthly]
Terminated PHASE3
-
Mar 2017 — May 2017 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Jan 2017 — Mar 2017 [monthly]
Recruiting PHASE3
First recorded
Apr 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clinipace Worldwide
- ICON plc
- MEDA Pharma GmbH & Co. KG
- Trium Analysis Online GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Altötting, Germany , Bad Homburg, Germany , Berlin, Germany , Bielefeld, Germany , Bochum, Germany , Bonn, Germany , Braunschweig, Germany , Coesfeld, Germany , Dortmund, Germany and 20 more locations